The Ministerie van Buitenlandse Zaken (Ministry of Foreign Affairs) (BZ) of The Netherlands has committed to enhance its efforts in global health, having established a Dutch Global Health Strategy. The focus will be on strengthening health systems across the world and international cooperation in preparation for future pandemics.
The Medicines for Malaria Venture (MMV) is a product development partnership (PDP) working to address unmet medical needs for key populations, such as children, pregnant women and people suffering from relapsing and drug-resistant malaria. MMV holds a large portfolio of antimalarial projects worldwide, covering all stages of product development.
MedAccess is a UK-based social-finance enterprise accelerating access to vaccines, medicines, diagnostics and technologies for people in underserved communities. Founded by British International Investment, MedAccess brokers and finances agreements that enable suppliers and procurers to get products to health workers and patients more quickly. Its portfolio covers HIV/AIDS and syphilis, tuberculosis, malaria, and other neglected diseases.
The Korea International Cooperation Agency (KOICA) was established in April 1991 by the Korean Government as a governmental agency dedicated to providing grant aid programs. It operates both domestically and internationally as a development cooperation platform contributing to accomplish the Sustainable Development Goals (SDGS). Through its Global Disease Eradication Fund, KOICA partners with international non-governmental organisations and the private sector to prevent and eradicate infectious diseases in developing countries.
Irish Aid is the Irish Government’s programme for overseas development, managed by the Development Co-operation Division of the Department of Foreign Affairs. Irish Aid invests in research that focuses on improving the health of the poorest and most vulnerable communities, covering infectious diseases such as malaria and HIV, as well as vaccine development.
Initiative 5% is a facility implemented by the public agency Expertise France and complementing the Global Fund Initiative in building a more effective response to pandemics, with a focus on HIV/AIDS, malaria and tuberculosis, and strengthening the health impact of funded programmes for populations. Set up in 2011, it supports recipients in accessing Global Fund funding and improving the effectiveness of grants, mainly in French-speaking countries.
The Global Health Innovative Technology Fund (GHIT Fund) is an international public-private partnership between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome Trust, and United Nations Development Programme (UNDP). It facilitates global R&D partnerships for the discovery and development of new health technologies for the developing world and invests in these global R&D partnerships through a grant-making mechanism. Its portfolio covers drugs, vaccines, and diagnostics in infectious diseases, such as HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases.
The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organisation developing new treatments in the area of serious bacterial infections, with a focus on children and newborns, and sexually transmitted infections, such as gonorrhoea. Established by the World Health Organization (WHO) and the Drugs for Neglected Disease Initiative (DNDi) in 2016, GARDP is a core element of WHO’s Global Action Plan on Antimicrobial Resistance.
The Global AMR Innovation Fund (GAMRIF) is UK aid fund that supports research and development around the world to reduce the threat of antimicrobial resistance in low- and middle-income countries (LMICs). GAMRIF works with a range of organisations using bilateral partnerships, global research initiatives and product development partnerships, establishing global and international research partnerships, leveraging investments from partners and donors to support sustainable partnerships for AMR, and funding projects that aim to develop solutions specifically for LMICs.
The Foreign, Commonwealth and Development Office (FCDO) is the UK’s ministerial department responsible for foreign affairs and international development. A key FCDO priority is supporting research in infectious diseases, including developing new technologies and supporting health systems strengthening in low- and middle-income countries (LMICs). Among others, FCDO is working with the Bill & Melinda Gates Foundation (BMGF), CEPI, Wellcome Trust, the UK Department for Health and Social Care (DHSC), the Medical Research Council (MRC), and the WHO to drive forward the agenda on infectious disease preparedness.